Carlisle 公司

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for CSL LTD(CMXHF.US), With a Forecast Between $113.21 to $132.82
  \u5e02\u573a\u8d44\u8baf · 2026/8/19
• 公司公告
  CSL Ltd: U.S. Section 232 Tariffs on Pharmaceuticals
  ASX · 2026/4/7
• CSL Strikes US$1.6 Billion Licensing Deal for Rare Disease Drug | ASX:CSL
  Proactive Investors · 2026/10/5
• 评级变动
  D.A. Davidson Maintains Carlisle Companies(CSL.US) With Hold Rating, Raises Target Price to $410
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 公司公告
  Cara Therapeutics | SC 13D: Statement of acquisition of beneficial ownership by individuals-Vifor (International) Ltd.(13.5%),CSL Limited(13.5%)
  SEC · 2024/10/31
• 评级变动
  CSL Price Target Raised 15% to A$181.00/Share by UBS
  Dow Jones · 2026/8/19
• 评级变动
  CSL Raised to Accumulate From Hold by Ord Minnett CSL.AU
  Dow Jones · 2026/9/16
• CSL Raises US$1.5bn in Dual-Tranche Bond Deal to Refinance Debt
  TipRanks · 2026/10/7
• 评级变动
  RBC Capital Upgrades CSL LTD(CMXHF.US) to Buy Rating, Raises Target Price to $152.48
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• CSL Price Target Raised 10% to A$161.50/Share by Jefferies
  Dow Jones · 2026/10/6
• CSL to Roll Out New Haemonetics Plasma Platform Across U.S. Network
  TipRanks · 2026/10/8
• CSL Target Price Raised 31% to A$174.00/Share by MacquarieCSL.AU
  Dow Jones · 2026/9/30
• 评级变动
  Morgan Stanley Maintains CSL LTD(CMXHF.US) With Buy Rating, Cuts Target Price to $123.25
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 公司公告
  CSL Ltd: Update on U.S. Plasma Collection Network
  ASX · 2026/10/8
• 评级变动
  UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Maintains Target Price $129.7
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Goldman Sachs Maintains Carlisle Companies(CSL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/22
• 评级变动
  Morgans Maintains CSL LTD(CMXHF.US) With Buy Rating, Cuts Target Price to $134.13
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• 评级变动
  A Quick Look at Today's Ratings for CSL LTD(CMXHF.US), With a Forecast Between $113.89 to $147.34
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 公司公告
  CSL Ltd: Agreements with U.S. on Drug Prices and Manufacturing
  ASX · 2026/9/1
• 公司公告
  CSL Ltd: CSL prices US$1.5 billion in Corporate Bonds
  ASX · 2026/10/7
• 公司公告
  Ranger Energy Services | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Charles S. Leykum(15.6%),CSL Energy Opportunity GP II, LLC(15.4%), etc.
  SEC · 2024/5/9
• 评级变动
  CSL Price Target Raised 25% to A$150.00/Share by Bell Potter
  Dow Jones · 2026/8/19
• 评级变动
  CSL Price Target Raised 23% to A$146.50/Share by Jefferies
  Dow Jones · 2026/8/19
• 公司公告
  CSL Ltd: CSL announces sale of Ruide operations.
  N/A · 2024/8/30
• 评级变动
  UBS Maintains CSL LTD(CMXHF.US) With Buy Rating, Cuts Target Price to $110.47
  \u5e02\u573a\u8d44\u8baf · 2026/7/31

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。